뉴스

The Pentagon added Chinese pharmaceutical contractor WuXi AppTec to a list of entities it alleges are linked to the country’s military, but the blacklisting will not stop multinational drug makers from collaborating with China’s biopharmaceutical firms, according to analysts. “We view minimal impact given multinational [companies] in pharma still prefer made-in-China for cost efficiency,” said Cui Cui, head of healthcare research for Asia at Jefferies. “Meanwhile, Wuxi AppTec earnings visibility...

South China Morning Post

중도 성향

정치

부정적

The next tech war? Why biotech may become a new US-China battleground

The wide-ranging geopolitical rivalry between Beijing and Washington could soon expand into biotechnology, raising the prospect of fresh tensions even as American pharmaceutical firms have turned to China’s fast-growing industry for new drug candidates. Biotech in the world’s second-largest economy has long been viewed as a predominantly low-cost manufacturing base with opportunities arising from its vast domestic market. But years of sustained investment, cost advantages and faster development...

RTHK News (Hong Kong)

중도 성향

기타

Robots take dispensing load at community health centre

The Hospital Authority has said its smart warehouse management system which uses automated robots has successfully streamlined the handling of medicine, freeing up pharmacists to focus on patient care. The system was implemented in late 2024 at the North District Community Health Centre, where robots carry designated drug shelves to workstations at the centre's warehouse to replenish drugs. This means pharmacists no longer need to search for and transport drugs. The authority's chief pharmacist William Chui pointed out that the time required for retrieving medicine has decreased from 20 minutes to only a few minutes. "If the pharmacists engage in the storage of the drugs, or other [logistical] or technical operations, they would spend less time on patients directly, so that's why we introduced this smart warehouse management system," Chui said. "It can provide more time for pharmacists, healthcare professionals or dispensers to take care of our patients. "The second benefit of introducing this new smart system is to ensure or enhance the medication system, and also for increasing the storage space by 20 percent," he added. Betty Leung, the pharmacy department manager at the North District Hospital – which also uses some of the medicine from the North District Community Health Centre – explained that the system has eliminated the need to reserve space for trolleys used for carrying medicine, increasing storage capacity. She also pointed out that there is a backup plan if the system fails. "We can call for a 24-hour support, and worse comes to worst, we can revert to our old mechanism of having staff going into the drug store to get the drugs." She added that the system also monitors the medicine inventory in real time, which would ensure no drugs would be used past their expiry date. Leung also said there are plans to expand the use of the smart warehouse management system. "In [health facilities that will be redeveloped], or new hospitals, new clinics, we can deploy this warehouse system to enhance the service." Edited by Aaron Tam

South China Morning Post

중도 성향

기타

긍정적

China’s Innovent Biologics signs US$10.5 billion Pfizer deal for 12 cancer drug trials

China’s Innovent Biologics has signed a global collaboration with pharmaceutical giant Pfizer worth up to US$10.5 billion to jointly develop 12 cancer treatment programmes. The Hong Kong-listed drug maker said it would receive an upfront payment of US$650 million from Pfizer, and it is eligible for up to US$9.85 billion tied to development, regulatory and commercial milestone payments, according to an exchange filing on Friday. Innovent, which is based in Suzhou in China’s eastern Jiangsu...

South China Morning Post

중도 성향

기타

긍정적

China’s drug regulator clears wave of home-grown innovative medicines amid biotech boom

Home-grown innovative drugs make up most of the medicines China’s drug regulator has approved for sale so far this year, underscoring the country’s biotech boom. Of the 19 innovative drugs cleared by the National Medical Products Administration (NMPA), 15 came from domestic companies, according to the regulator’s website as of May 21. These include sonrotoclax, developed by global biopharmaceutical firm BeOne, for treating certain adult blood cancers. The regulator overhauled its approval...

1 / 1 (총 5건)

RTHK News (Hong Kong)

중도 성향

기타